Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for P3 Health Partners (PIII) over the last 5 years, with Q3 2025 value amounting to $21.0 million.

  • P3 Health Partners' Depreciation & Amortization (CF) fell 295.3% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.3 million, marking a year-over-year decrease of 256.3%. This contributed to the annual value of $86.1 million for FY2024, which is 71.19% down from last year.
  • Per P3 Health Partners' latest filing, its Depreciation & Amortization (CF) stood at $21.0 million for Q3 2025, which was down 295.3% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, P3 Health Partners' Depreciation & Amortization (CF) peaked at $22.0 million during Q4 2022, and registered a low of $332548.0 during Q1 2021.
  • In the last 5 years, P3 Health Partners' Depreciation & Amortization (CF) had a median value of $21.5 million in 2023 and averaged $17.1 million.
  • Per our database at Business Quant, P3 Health Partners' Depreciation & Amortization (CF) surged by 644101.06% in 2022 and then crashed by 295.3% in 2025.
  • P3 Health Partners' Depreciation & Amortization (CF) (Quarter) stood at $356203.0 in 2021, then soared by 6076.81% to $22.0 million in 2022, then fell by 1.67% to $21.6 million in 2023, then dropped by 2.22% to $21.2 million in 2024, then dropped by 0.57% to $21.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $21.0 million in Q3 2025, compared to $21.1 million in Q2 2025 and $21.1 million in Q1 2025.